Opinion
Video
The Role of Androgen Receptor-Targeted Therapy in the Treatment of mCRPC
Author(s):
Key opinion leaders explore the role of androgen receptor-targeted therapy in mCRPC.
Video Player is loading.
- How do androgen receptor-targeted therapies, including abiraterone and enzalutamide, fit into the treatment paradigm, and when might you choose an androgen receptor-targeted therapy over other treatment options, or vice versa?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
Approaching Corticosteroid Selection With Abiraterone in Patients With High-Risk Localized or Locally Advanced Prostate Cancer
Incorporating Micronized Abiraterone and Low-Fat Meal Dosing: Monitoring Efficacy and Tolerability
The Growing Call for Combination Therapy in NMIBC Treatment
Optimizing NMIBC Treatment Through Sequencing and Patient Preference
Managing Abiraterone Intolerance: Alternative Dosing Strategies in Practice
Decision-Making and Multidisciplinary Counseling for Nodal Involvement on PSMA PET
Rethinking First-Line Treatments: Will BCG Continue to Be the Standard in NMIBC?
In the Pipeline: Novel Treatment Delivery Methods for NMIBC
RX Review: Implementing mitomycin for LG-IR-NMIBC in clinical practice
RX Review: TURBT vs chemoablation for low-grade, intermediate-risk NMIBC
Related Content
